Investigation of Novel and Established Therapies in a Human Intravenous Lipopolysaccharide Model of Sepsis

PHASE1/PHASE2Not yet recruitingINTERVENTIONAL
Enrollment

65

Participants

Timeline

Start Date

December 1, 2024

Primary Completion Date

February 1, 2026

Study Completion Date

July 1, 2026

Conditions
SepsisFluid OverloadEndothelial DysfunctionMicrocirculation
Interventions
DRUG

Imatinib

Pre-treatment with 600mg Imatinib administered 1 hour prior to intravenous LPS.

DRUG

Compound sodium lactate solution

Total of 30 ml/kg administered 90 minutes following intravenous LPS. 30mls/kg (maximum volume of 2500mls) administered in two divided doses (15mls/kg) intravenously. Each bolus will be administered at a fixed rate of 999mls/hr.

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

Medical Research Council

OTHER_GOV

collaborator

The Royal College of Anaesthetists

OTHER

lead

Belfast Health and Social Care Trust

OTHER